Neos Therapeutics Inc. (NASDAQ:NEOS)‘s stock had its “buy” rating restated by research analysts at BMO Capital Markets in a note issued to investors on Tuesday. They presently have a $15.00 price objective on the stock. BMO Capital Markets’ price target suggests a potential upside of 121.89% from the stock’s current price.

Shares of Neos Therapeutics (NASDAQ:NEOS) opened at 6.76 on Tuesday. Neos Therapeutics has a 12-month low of $6.33 and a 12-month high of $22.02. The stock’s market cap is $108.63 million. The firm has a 50-day moving average price of $7.49 and a 200 day moving average price of $9.06.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.16) by $0.49. Neos Therapeutics had a negative return on equity of 80.10% and a negative net margin of 968.81%. The business had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.48 million. Equities research analysts predict that Neos Therapeutics will post ($5.39) EPS for the current fiscal year.

In other Neos Therapeutics news, CFO Richard I. Eisenstadt purchased 3,710 shares of Neos Therapeutics stock in a transaction on Thursday, August 25th. The stock was bought at an average price of $6.82 per share, for a total transaction of $25,302.20. Following the transaction, the chief financial officer now owns 3,710 shares of the company’s stock, valued at approximately $25,302.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.85% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC raised its stake in shares of Neos Therapeutics by 10.0% in the second quarter. ProShare Advisors LLC now owns 13,622 shares of the company’s stock valued at $126,000 after buying an additional 1,233 shares during the period. Geode Capital Management LLC raised its stake in shares of Neos Therapeutics by 5.4% in the first quarter. Geode Capital Management LLC now owns 38,698 shares of the company’s stock valued at $417,000 after buying an additional 1,997 shares during the period. State Street Corp raised its stake in shares of Neos Therapeutics by 20.0% in the first quarter. State Street Corp now owns 64,825 shares of the company’s stock valued at $698,000 after buying an additional 10,786 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Neos Therapeutics by 73.1% in the second quarter. Bank of New York Mellon Corp now owns 38,008 shares of the company’s stock valued at $353,000 after buying an additional 16,046 shares during the period. Finally, Teachers Advisors Inc. raised its stake in shares of Neos Therapeutics by 289.6% in the second quarter. Teachers Advisors Inc. now owns 21,924 shares of the company’s stock valued at $203,000 after buying an additional 16,296 shares during the period. Institutional investors and hedge funds own 37.73% of the company’s stock.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

5 Day Chart for NASDAQ:NEOS

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.